This Article Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by VANCE, M. L. Articles by MOLITCH, M. E. Search for Related Content PubMed PubMed Citation Articles by VANCE, M. L. Articles by MOLITCH, M. E.

CV 205–502 Treatment of Hyperprolactinemia^*

Department of Internal Medicine, Division of Endocrinology and Metabolism, University of Virginia Medical Center (M.L.V.) Charlottesville, Virginia 22908
The Department of Obstetrics and Gynecology, University of California (J.R.C., R.J.C.) Davis, California 95816
The Department of Obstetrics and Gynecology, University of California (C.R.) Los Angeles, California 90024
The Department of Obstetrics and Gynecology, University of Alabama (E.R., R.E.B.) Birmingham, Alabama 35294
The Department of Obstetrics and Gynecology (M.M.M.) and Center for Endocrinology, Metabolism and Nutrition, Northwestern University Chicago, Illinois 60611 (M.E.M.)

Address all correspondence and requests for reprints to: Mary Lee Vance, M.D., Box 511, University of Virginia Medical Center, Charlottesville, Virginia 22908.

CV 205–502 is a nonergot oral dopamine agonist with specific D2 activity, which has a prolonged suppressive effect on serum PRL and may have fewer side-effects than other dopamine agonists. We treated 26 hyperprolactinemic women with this compound given as a single bedtime (hs) dose for up to 12 weeks. All had gonadal dysfunction, either amenorrhea or oligomenorrhea, and 15 had galactorrhea. The initial and subsequent doses were administered in a randomized fashion; the initial dose ranged from 0.01–0.05 mg, and the dose at 12 weeks ranged from 0.03–0.09 mg. The women were evaluated every 2 weeks, and the dose was increased by 0.02 mg every 4 weeks if the serum PRL level was greater than 20 µg/h. Of the 26 women initially enrolled, 24 completed 12 weeks of therapy, and 2 discontinued therapy because of side-effects. Thirteen women (54%) had return of menses, and 12 (80%) had either a decrease in or disappearance of galactorrhea. Serum PRL concentrations decreased to a variable degree in all patients; 13 (54%) achieved a normal serum PRL level (20 µg/h). The mean (± SE) pretreatment serum PRL concentration was 129 ± 34, and it was 29.9 ± 5.9 µg/L after 12 weeks of treatment (P = 0.005). The mean (±SE) percent reduction in serum PRL was 66.5 ± 5.0% (median, 78.0%). A dose response was not demonstrated (r = –0.08; P = 0.70) among the 6 dose groups during the last 4 weeks of therapy. In 5 women, serum PRL levels, measured frequently for 24 h after treatment remained low. Side-effects after the initiation of therapy included nausea, headache, and morning fatigue in 10 women. These symptoms caused 2 women to discontinue therapy; they subsided in the other women. An optimal dose was not determined and will probably need to be determined by titration in each patient. CV 205–502, given once daily, appears to be a safe and effective alternative to other dopamine agonists in the treatment of hyperprolactinemia.

^* This work was supported in part by General Clinical Research Center USPHS Grant RR-00847 (to University of Virginia) and a Sandoz Research Institute award.

Received July 20, 1988.

This article has been cited by other articles:

				M. P. Gillam, M. E. Molitch, G. Lombardi, and A. Colao Advances in the Treatment of Prolactinomas Endocr. Rev., August 1, 2006; 27(5): 485 - 534. [Abstract] [Full Text] [PDF]

				A. Barlier and P. Jaquet Quinagolide - a valuable treatment option for hyperprolactinaemia Eur. J. Endocrinol., February 1, 2006; 154(2): 187 - 195. [Abstract] [Full Text] [PDF]

				M. L. Vance Hypopituitarism N. Engl. J. Med., June 9, 1994; 330(23): 1651 - 1662. [Full Text]

				D. Tyson, D. Reggiardo, C. Sklar, and R. David Prolactin-Secreting Macroadenomas in Adolescents: Response to Bromocriptine Therapy Arch Pediatr Adolesc Med, October 1, 1993; 147(10): 1057 - 1061. [Abstract] [PDF]

				M. L. Vance, M. Lipper, A. Klibanski, B. M. K. Biller, N. A. Samaan, and M. E. Molitch Treatment of Prolactin-Secreting Pituitary Macroadenomas with the Long-acting Non-Ergot Dopamine Agonist CV 205-502 Ann Intern Med, May 1, 1990; 112(9): 668 - 673. [Abstract] [PDF]